CRISPR Therapeutics is a leading gene editor. The company was founded by Nobel laureate Emmanuelle Charpentier and Rodger Novak, associated with Bayer. The company has established cooperation with the German pharmaceutical giant and Vertex Pharmaceuticals.
- Gene editing has a chance to revolutionize medicine and find solutions to eliminate many previously incurable genetic diseases as it give scientists the ability to change an organism's DNA;
- CRISPR Therapeutics has already implemented the Federal Drug Administration (FDA) approved drug CTX001 for beta thalassemia and sickle cell disease;
- As part of the work on CTX001, the Vertex concern started cooperation with CRISPR Therapeutics and acquired 60% of shares in the research program, in which it has already invested USD 900 million. The estimated value of this program is $ 9 billion;
- Both companies have announced breakthrough clinical data on the CTX001 program. They have been approved for presentation at the Congress of the European Hematology Association (EHA) which is scheduled for June 10. Vertex also announced three other research projects approved for presentation at the EHA meeting.
CRISPR Therapeutics (CRSP.US) stock price was moving in a downward trend in recent months as popularity of medical companies diminished. The declines halted around $ 40.00 level, where a double bottom formation may be forming. The company has relatively solid fundamental indicators, such as a price-earnings ratio of around 16 and a price-to-book ratio of around 2.2, which can be perceived as attractive compared to other pharmaceutical companies' valuations. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
